| 06.28.22 | Cancer vaccine gets US defense department backing; T cells to boost CAR-T potential

Laden...

2 jaren geleden

Html
Tekst

Webinar: Increase Productivity in Discovery Labs with Data Pipelining

Wednesday, July 13, 2022 | 11:00am ET / 8:00am PT

BIOVIA has pioneered data pipelining to address data science and informatics challenges in research and engineering organizations. In this webinar you will learn how to rapidly create virtual screening pipelines and share them as 'best practices' and more. Register now.

Today's Rundown

Vaccine combo hits back at treatment-resistant cancer in fight backed by US Department of Defense Manipulating T-cell fate to improve CAR-T therapy in solid tumors Researchers look to the stars for new Alzheimer's target Enzyme inhibitor could counter bad 'seeds' that let leukemia bounce back 'The Top Line' podcast: Why we need an Alzheimer's moonshot, a controversial take on diversity in biotech, plus this week's headlines COVID-19 tracker: Omicron variant could cause global surge, WHO says; J&J recipients opt for other boosters The 15 highest paid biopharma CEOs of 2021

Trending Topic: Cell & Gene Therapy
Read on to understand how the industry is addressing gene therapy and cell therapy research and development.

Featured Story

Vaccine combo hits back at treatment-resistant cancer in fight backed by US Department of Defense

By Gabrielle Masson

New research shows a one-two hit from an experimental vaccine combo is significantly more effective at fighting off treatment-resistant cancers in animal models than either approach by itself—and the Department Defense is throwing down money to move the science into the clinic.


This week's sponsor is Lonza.

Manipulating T-cell fate to improve CAR-T therapy in solid tumors

By Angus Liu

Inhibiting a protein could boost the efficacy of CAR-T cells by letting newly activated T cells preferentially differentiate toward long-lasting memory T cells rather than the short-living effector cells, scientists at St. Jude Children’s Research Hospital have shown.

Researchers look to the stars for new Alzheimer's target

By Gabrielle Masson

To help crack Alzheimer's disease, researchers are looking to a North Star—or, more accurately, a star-shaped cell in the brain that could play a role in progression of the neurodegenerative disease.

Enzyme inhibitor could counter bad 'seeds' that let leukemia bounce back

By James Waldron

Leukemia is notorious for being very aggressive and hard to eradicate from the body. The culprits are leukemic stem cells—known as “seed” cells—that drive resistance to chemotherapy and can trigger a relapse of the cancer.

'The Top Line' podcast: Why we need an Alzheimer's moonshot, a controversial take on diversity in biotech, plus this week's headlines

By Teresa Carey

This week on "The Top Line," we discuss why scientists say we need an Alzheimer's moonshot. We also talk about a controversial take on diversity during a panel at the BIO conference. Plus, we'll hear award-winning ads that tug at our heartstrings.

COVID-19 tracker: Omicron variant could cause global surge, WHO says; J&J recipients opt for other boosters

By Kevin Dunleavy,Fraiser Kansteiner,Emmy Lucas,Noah Higgins-Dunn

A new COVID-19 variant, the omicron variant, could soon surge, the World Health Organization said. Those who received the Johnson & Johnson vaccine are often opting for other vaccines as a booster. Plus more.

The 15 highest paid biopharma CEOs of 2021

By Fraiser Kansteiner,Eric Sagonowsky,Angus Liu,Kevin Dunleavy,Zoey Becker

In a year in which biopharma revenues increased dramatically, especially among companies that brought COVID-19 products to the market, many firms laid out eye-popping pay packages for their chief executives. Bookending this year's list are longtime CEOs who retired from powerhouse U.S. companies during the year—No. 1 Alex Gorsky of Johnson & Johnson and No. 15 Ken Frazier of Merck.